STOCK TITAN

Edwards Lifesciences Corp Stock Price, News & Analysis

EW NYSE

Welcome to our dedicated page for Edwards Lifesciences news (Ticker: EW), a resource for investors and traders seeking the latest updates and insights on Edwards Lifesciences stock.

Edwards Lifesciences Corp (NYSE: EW) delivers transformative medical technologies for heart valve disease and critical care monitoring. This news hub provides investors and healthcare professionals with timely updates on the company’s advancements in lifesaving innovations.

Track all official press releases, financial announcements, and clinical milestones in one centralized location. Our curated collection includes updates on transcatheter valve therapies, hemodynamic monitoring systems, regulatory approvals, and global partnership initiatives.

Stay informed about quarterly earnings, R&D breakthroughs, and strategic expansions shaping EW’s leadership in cardiovascular care. Bookmark this page for direct access to verified information supporting informed analysis of Edwards Lifesciences’ market position.

Rhea-AI Summary

Edwards Lifesciences (NYSE: EW) faces opposition from the U.S. Federal Trade Commission (FTC) regarding its proposed acquisition of JenaValve Technology. The FTC has moved to block the transaction, which Edwards believes would enhance treatment options for patients with aortic regurgitation (AR).

Despite the regulatory challenge, Edwards plans to pursue approval, expecting a final determination by Q1 2026. The company has revised its 2025 guidance, maintaining revenue projections while increasing adjusted EPS guidance to $2.45-$2.55 from $2.40-$2.50. Q3 adjusted EPS guidance remains largely unchanged.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.8%
Tags
-
Rhea-AI Summary

Edwards Lifesciences (NYSE: EW) reported strong Q2 2025 financial results with sales growing 11.9% to $1.53 billion. The company's TAVR sales increased 8.9% to $1.1 billion, while TMTT sales reached $134.5 million, growing 61.9% year-over-year. Surgical sales grew 7.7% to $267 million.

The company increased its 2025 guidance, now projecting total sales growth of 9-10% to $5.9-6.1 billion, with TAVR sales guidance raised to 6-7%. Adjusted EPS guidance was raised to the high end of $2.40-$2.50. Q2 EPS was $0.57, with adjusted EPS at $0.67.

Notable achievements include SAPIEN platform's approval for asymptomatic patients in U.S. and Europe, CE Mark approval for SAPIEN M3, and strong performance across all product groups. The company maintains a stable competitive position and pricing globally.

[ "Total sales grew 11.9% to $1.53 billion, exceeding expectations", "TMTT sales surged 61.9% year-over-year to $134.5 million", "Increased 2025 sales growth guidance to 9-10% from 8-10%", "SAPIEN platform received approval for asymptomatic patients in US and Europe", "Strong cash position with approximately $3 billion in cash and cash equivalents", "Gross profit margin of 77.5% maintained in line with expectations" ]
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.44%
Tags
-
Rhea-AI Summary

Edwards Lifesciences (NYSE: EW), the global leader in structural heart innovation, has scheduled its Q2 2025 earnings conference call for July 24, 2025, at 5:00 p.m. ET. The company will release its operating results for the quarter ended June 30, 2025, after market close on the same day.

Investors can participate by dialing (877) 704-2848 or (201) 389-0893. The call will be available live and archived on the company's investor relations website at ir.edwards.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
conferences earnings
Rhea-AI Summary
Edwards Lifesciences (NYSE: EW) presented compelling evidence at EuroPCR 2025 demonstrating the benefits of early intervention in severe aortic stenosis (AS) patients. A real-world study of over 24,000 patients showed that treating AS before symptom development led to $36,000 lower healthcare costs per patient at 1 year, 2.2 fewer days of hospital stay, and 80% reduction in heart failure hospitalizations. Notably, delaying treatment until disease progression resulted in a seven times higher mortality rate within one year after aortic valve replacement. The study reinforces the importance of early referral to Heart Valve Teams and challenges the "watchful waiting" approach for severe AS management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.72%
Tags
none
-
Rhea-AI Summary

Edwards Lifesciences (NYSE: EW), the global leader in structural heart innovation, has announced its participation in the BofA Securities 2025 Health Care Conference on May 13, 2025. CEO Bernard Zovighian and CFO Scott Ullem will engage in a fireside chat at 10:40 a.m. Pacific Time. The discussion will be accessible via live webcast on Edwards' investor relations website, with a recorded version available later that day.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.25%
Tags
conferences
-
Rhea-AI Summary

Edwards Lifesciences (NYSE: EW) has received FDA approval for its SAPIEN 3 TAVR (transcatheter aortic valve replacement) platform to treat asymptomatic severe aortic stenosis (AS) patients, marking the first such approval for asymptomatic cases. The approval is based on the EARLY TAVR trial results, which showed superior outcomes for TAVR compared to watchful waiting.

Key trial results with 3.8 years median follow-up showed that 26.8% of TAVR patients experienced death, stroke, or unplanned cardiovascular hospitalization, compared to 45.3% in the clinical surveillance group. The study included 455 patients in the TAVR arm and 446 in the surveillance arm. Without treatment, 1 in 10 symptomatic severe AS patients may die within five weeks.

The SAPIEN platform has treated over 1 million patients worldwide and is the most studied valve platform, with nine publications in The New England Journal of Medicine.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
Rhea-AI Summary

Edwards Lifesciences (NYSE: EW) reported strong Q1 2025 financial results with total sales growing 6.2% to $1.41 billion. The company's TAVR sales reached $1.05 billion, growing 3.8% (5.4% constant currency), while TMTT sales showed impressive growth of 58% to $115 million.

Key financial metrics include Q1 EPS of $0.62 (adjusted EPS $0.64) and a gross profit margin of 78.7%. The company received SAPIEN M3 CE Mark approval and achieved multiple TAVR study milestones.

Looking ahead, Edwards raised its TMTT sales guidance to $530-550 million and increased total company sales guidance to $5.7-6.1 billion for 2025. The company reaffirmed its adjusted EPS guidance of $2.40-2.50, accounting for JenaValve dilution and tariff impacts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.63%
Tags
-
Rhea-AI Summary

Edwards Lifesciences (NYSE: EW) announced groundbreaking eight-year data demonstrating superior outcomes for patients receiving aortic surgical valves with their proprietary RESILIA tissue technology compared to non-RESILIA tissue bioprosthetic valves.

The study of 947 patients showed remarkable durability metrics, with 99.3% freedom from structural valve deterioration (SVD) in the RESILIA group versus 90.5% in the non-RESILIA group. Additionally, freedom from reoperation due to SVD was 99.2% for RESILIA tissue versus 93.9% for non-RESILIA tissue.

RESILIA tissue is currently utilized across Edwards' surgical and transcatheter platforms, including INSPIRIS RESILIA, KONECT RESILIA, MITRIS RESILIA, and SAPIEN 3 Ultra RESILIA valves. Over 450,000 patients worldwide have been treated with Edwards' surgical or TAVR valves featuring RESILIA tissue, marking a significant milestone in structural heart disease treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Edwards Lifesciences (NYSE: EW) has scheduled its Q1 2025 earnings announcement for April 23, 2025, after market close. The company will host a conference call at 5:00 p.m. ET to discuss the quarterly results ending March 31, 2025.

Investors can participate by dialing (877) 704-2848 or (201) 389-0893. The call will be available live and archived on the company's investor relations website at ir.edwards.com.

Edwards Lifesciences, the global leader in structural heart innovation, focuses on developing breakthrough technologies and maintaining partnerships with healthcare stakeholders to deliver life-changing innovations to patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
conferences earnings
Rhea-AI Summary

Edwards Lifesciences (NYSE: EW) has received CE Mark approval for its SAPIEN M3 mitral valve replacement system, becoming the world's first transfemoral transcatheter mitral valve replacement therapy. The system is approved for treating patients with symptomatic moderate-to-severe or severe mitral regurgitation who are unsuitable for surgery or transcatheter edge-to-edge therapy.

The SAPIEN M3 system utilizes a novel two-step procedure, delivering a dock that wraps around native mitral leaflets followed by valve placement. The system is delivered through a 29F outer diameter steerable guide sheath via the femoral vein. Built on Edwards' proven SAPIEN platform, which has been used in over 8,000 mitral procedures, the technology has shown substantial reduction in mitral regurgitation and improved quality of life.

Results from the ENCIRCLE pivotal trial are expected in late 2025, with a planned European Post-Market Clinical Follow-up Study tracking patients for up to five years.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.68%
Tags
none

FAQ

What is the current stock price of Edwards Lifesciences (EW)?

The current stock price of Edwards Lifesciences (EW) is $78.18 as of August 14, 2025.

What is the market cap of Edwards Lifesciences (EW)?

The market cap of Edwards Lifesciences (EW) is approximately 45.2B.
Edwards Lifesciences Corp

NYSE:EW

EW Rankings

EW Stock Data

45.17B
580.11M
0.91%
89.29%
1.18%
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States
IRVINE